

## Edward Vital PhD FRCP

Professor of Translational Medicine  
Honorary Consultant Rheumatologist

### Highlights

- Extensive clinical and translational research programme with over €10m research funding
- Global leadership roles: BILAG, SLEuro, TRM-SLE, Transform Lupus
- Founder and chair of the Lupus Forum: global educational initiative for clinicians treating SLE
- Invited speaker at international conferences
- Chief investigator of NIHR multicentre RCT for biologic therapy in early SLE
- European Research Council fellowship for translational studies in pre-clinical SLE
- Consultancy work: steering committee and DSMB roles, author or lead author on key publications
- 145 peer-reviewed publications

### Affiliations

- NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds

### Contact Details

Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, LS7 4SA,  
Tel: 0113 2755111, Email: [Edward.Vital@leeds.ac.uk](mailto:Edward.Vital@leeds.ac.uk)

### General Medical Council registration

4739885 (license to practice on specialist register)

### Qualifications

|          |                                   |          |
|----------|-----------------------------------|----------|
| MB ChB   | University of Manchester          | 24/07/00 |
| MRCP(UK) | Royal College Physicians (London) | 29/07/04 |
| PhD      | University of Leeds               | 23/04/12 |

### Education

1995-2000 University of Manchester  
2009-2012 University of Leeds

### Professional Membership

- Fellow of the Royal College of Physicians London
- Medical Protection Society
- British Society for Rheumatology

### International Leadership Roles

- Founder and Chair: Lupus Forum (global educational website, [lupus-forum.com](http://lupus-forum.com))
- General Secretary: SLEuro
- Global Steering Committee Chair: TransformLupus,
- Steering Committee Member and MSK workstream lead: Treatment Response Measure for SLE (international consortium)

### National Leadership Roles

- Chair, British Isles Lupus Activity Group (National collaborative clinical care and research group)
- Chair, British Society for Rheumatology Special Interest Group for SLE
- Chair Versus Arthritis Research Advisory Group for Autoimmune Rheumatic Diseases
- Lead Site, NIHR Immune Mediated Inflammatory Disease BioResource

### Editorial Board membership

- Lupus Science and Medicine
- Rheumatology

### **Invited Speaker (highlights)**

- EULAR 2021, 2022, 2023, 2024, 2026
- European Lupus Meeting 2022, 2026
- World Lupus Meeting 2025
- Lupus Academy 2023, 2024, 2025, 2026
- National conferences: UK, Japan, India, South Africa, Germany, Spain, Taiwan, Hungary, China, UAE, Saudi Arabia, Australia, Belgium, Israel, Netherlands

### **Previous Appointments**

- National Institute of Health Research Clinician Scientist, University of Leeds (2014-2019)
- National Institute of Health Research Clinical Lecturer, University of Leeds (2012 – 2014)
- National Institute of Health Research Doctoral Research Fellow, University of Leeds, (2009 – 2011)
- Specialist Registrar, Rheumatology, Yorkshire Deanery (2005-2012)

### **Research Group**

- Associate professor, NIHR Clinical lecturer, post-doctoral researcher, 2 clinical PhD students, 2 laboratory PhD students, 2 research nurses, study coordinator, clinical trials assistant

### **Prizes**

- Gold Award: Digital Health Awards 2023
- Grand Award: Awards for Publication Excellence 2022
- Michael Mason Prize: British Society for Rheumatology 2019
- Emerging Leader Award: Medical Research Foundation 2018
- International Scholarship: Japanese College of Rheumatology 2011

### **Research Grants**

>€10.5m research income as PI or Co-I

- CI: First Line Rituximab for SLE Trial (FIRST), NIHR. £2.6m (2025-2030)
- CI, Prevent-SLE, European Research Council, 2023 – 2028. €2m
- Co-I and workstream lead, MASTERPLANS (MRC Stratified Medicine Consortium). £5.1m (2015-2020)
- CI, Improving the evaluation and implementation of biologic therapies in Systemic Lupus Erythematosus. NIHR. £1m. (2014 – 2019)
- CI, Validation of the Lupus Arthritis and Musculoskeletal Disease Activity Instrument, MRC. (2019 – 2022). £74k
- CI, Investigating the role of the skin in the earliest initiation of systemic lupus erythematosus, Lupus UK 2021 – 2023. £25k.
- CI, Rituximab Objective Outcome Measures Trial in SLE, Hexal. £375k. 2019 - 2021
- CI, Emerging Leaders Award. Medical Research Foundation, £20k. 2019 - 2020
- CI, Immunophenotyping Connective Tissue Disease for Optimal Use of Interferon-Targeted Therapies, £250k, AstraZeneca
- CI, Predicting response to rituximab in seronegative rheumatoid arthritis. Roche. £70,000 2015 - 2017
- CI, Understanding Cutaneous Response to Rituximab in Systemic Lupus Erythematosus. Academy of Medical Sciences. £29,072
- CI, Ultrasound for Evaluation of Musculoskeletal Lupus. Lupus UK. £57,832
- Co-I, Identification of targets to prevent scarring outcome in cutaneous Lupus. Lupus UK £36,010
- CI, Prediction of Systemic Lupus Erythematosus in At-Risk individuals using a novel type 1 interferon biomarker, MRC CiC, £70,000
- CI, Dissecting the role of interferons in the onset of systemic lupus erythematosus, £25K, LupusUK
- Co-I, Plucked hair follicles as a diagnostic test in lupus alopecia, £25K, LupusUK
- CI, Magnetic Resonance Imaging in Lupus Arthritis, £25K, LupusUK (2025-2026)

### **PUBLICATIONS**

H-index: 49

145 pubmed listed publications 14,803 citations. 2,976 citations in 2025. Highest cited publication = 4,250.

## PUBLICATIONS FULL LIST

### Recent Highlights (Senior Author)

- Psarras A, Alase A, Antanaviciute A, Carr IM, Md Yusof MY, Wittmann M, Emery P, Tsokos GC, Vital EM. Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity. *Nature Communications* 11, 6149 (2020).
- Carter L, Md Yusof MY, Wigston Z, Plant D, Wenlock S, Alase A, Psarras A, **Vital EM**. Blood RNA-sequencing across the continuum of ANA-positive autoimmunity reveals insights into initiating immunopathology *Ann Rheum Dis*. 2024.
- Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Morand EF, **Vital EM**, Petri M, van Vollenhoven R, Wallace DJ, Mosca M, Furie RA, Silk ME, Dickson CL, Meszaros G, Jia B, Crowe B, de la Torre I, Dörner T. *Lancet*. 2023 Mar 25;401(10381):1001-1010.
- Rodríguez-Carrio J<sup>1\*</sup>, Burska AN<sup>2\*</sup>, Conaghan PG<sup>1</sup>, Dik WA<sup>3</sup>, Biesen R<sup>4</sup>, Eloranta ML<sup>5</sup>, Cavalli G<sup>6</sup>, Visser M<sup>7</sup>, Boumpas D<sup>8</sup>, Bertsias G<sup>9</sup>, Wahren-Herlenius M<sup>10,11</sup>, Rehwinkel J<sup>12</sup>, Frémond ML<sup>13</sup>, Crow MK<sup>14</sup>, Ronnblom L<sup>5</sup>, Versnel MA<sup>15‡</sup>, **Vital EM**<sup>2‡</sup> 2022 EULAR Points to Consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice. *Ann Rheum Dis* 2023
- Md Yusof MY, Psarras A, El-Sherbiny YM, Hensor EMA, Dutton K, Ul-Hassan S, Zayat AS, Shalhaf M, Alase A, Wittmann M, Emery P, **Vital EM**. Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status. *Ann Rheum Dis*. 2018 Oct;77(10):1432-1439.
- Md Yusof MY, Shaw D, El-Sherbiny YM, Dunn E, Rawstron AC, Emery P, **Vital EM**. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. *Ann Rheum Dis*. 2017 Nov;76(11):1829-1836.
- Psarras A, Wittmann M, **Vital EM**. Emerging concepts of type I interferons in SLE pathogenesis and therapy. *Nat Rev Rheumatol*. 2022 Oct;18(10):575-590.
- Carter L, Ehrenstein MR, **Vital EM**. Evolution and trajectory of B cell targeted therapies in rheumatic diseases. *Lancet Rheumatology*. 2025
- Stockfelt M, Teng O, **Vital EM**. Opportunities and limitations of B cell depletion approaches in SLE. *Nature Reviews Rheumatology*, 1-16, 2025.
- Psarras A. and **Vital EM**. Keratinocytes: from passive targets to active mediators of systemic autoimmunity. *Sci Transl Med*. 2022 Apr 27;14(642)

### Original Research papers

1. Mucke J, Bertsias G, Aringer M, Arnaud L, Boström C, Cervera R, Chehab G, Cziráj L, Dreyer LW, Inês L, Jacobsen S, Nielsen CK, Marasco E, Mosca M, Myllys K, Pamfil C, Pego-Reigosa JM, Richter JG, Sciascia S, Tamirou F, Tsang-A-Sjoe M, **Vital EM**, Van Vollenhoven R, Wincup C, Schneider M. EULAR recommendations for a core dataset to support clinical care and translational and observational research in systemic lupus erythematosus. Taskforce for development of EULAR recommendations for a core dataset to support clinical care and translational and observational research in systemic lupus erythematosus. *Ann Rheum Dis*. 2025 Oct;84(10):1621-1631.
2. Abacar K, De Marco G, Weddell J, Meridor K, Macleod T, Scarsbrook A, Mankia K, **Vital E**, Barr A, Pease C, Marzo-Ortega H, Mackie SL, McGonagle D. Late-Onset Spondyloarthritis Presenting as Glucocorticoid-Resistant Polymyalgia Rheumatica: A Hitherto Underappreciated Entity in Which Tumor Necrosis Factor or Interleukin -17 Blockade May Have a Therapeutic Role. *Arthritis Rheumatol*. 2026 Jan;78(1):131-140.

3. Wiley MM, Radziszewski M, Khatri B, Joachims ML, Tessneer KL, Stolarczyk AM, Yao S, Li J, Pritchett-Frazee C, Johnston AA, Rasmussen A, Anaya JM, Aqrabi LA, Bae SC, Baecklund E, Björk A, Brun JG, Bucher SM, Dand N, Eloranta ML, Engelke F, Forsblad-d'Elia H, Fugmann C, Glenn SB, Gong C, Gotteberg JE, Hammenfors D, Imgenberg-Kreuz J, Jensen JL, Johnsen SJA, Jonsson MV, Kelly JA, Khanam S, Kim K, Kvarnström M, Mandl T, Martín J, Morris DL, Nocturne G, Norheim KB, Olsson P, Palm Ø, Pers JO, Rhodus NL, Sjöwall C, Skarstein K, Taylor KE, Tombleson P, Thorlacius GE, Venuturupalli SR, **Vital EM**, Wallace DJ, Radfar L, Brennan MT, James JA, Scofield RH, Gaffney PM, Criswell LA, Jonsson R, Appel S, Eriksson P, Bowman SJ, Omdal R, Rönnblom L, Warner BM, Rischmueller M, Witte T, Farris AD, Mariette X, Shiboski CH; Sjögren's International Collaborative Clinical Alliance (SICCA); Wahren-Herlenius M, Alarcón-Riquelme ME; PRECISEADS Clinical Consortium; Ng WF; UK Primary Sjögren's Syndrome Registry; Sivits KL, Guthridge JM, Adrianto I, Vyse TJ, Tsao BP, Nordmark G, Lessard CJ. Variants in the DDX6-CXCR5 autoimmune disease risk locus influence the regulatory network in immune cells and salivary gland. *Ann Rheum Dis*. 2025 Sep;84(9):1512-1527.
4. Arnaud L, Ruiz-Irastorza G, Aranow C, Bernatsky S, Dall'Era M, Adelowo O, Bae SC, Beretta L, Bonfa E, Cervera R, Chasset F, Clarke AE, Costedoat-Chalumeau N, Doria A, Espinosa G, Fanouriakis A, Fredi M, Gatto M, Gladman DD, Gomez-Puerta JA, Inanç M, Ines LS, Isenberg D, Izuka S, Khmelinskii N, Legge A, Macieira C, Monticelo OA, Morand EF, Muñoz-Louis R, Padjen I, Petri M, Piga M, Pons-Estel BA, Ramirez GA, Ramsey-Goldman R, Richez C, Sciascia S, Toro-Gutierrez CE, Van Vollenhoven RF, **Vital EM**, Gerosa M, Touma Z, Mosca M, Tani C; European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal, Diseases; Systemic Lupus Erythematosus International Collaborating Clinics group; European Lupus Society rare systemic lupus erythematosus taskforce member panel. ERN ReCONNECT-SLICC-SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestations. *Lancet Rheumatol*. 2025 Jul;7(7):e505-e518.
5. Askanase AD, **Vital EM**, Meier O, Turchetta A, Mao HA, Maller J, Ross Terres JA, Dall'Era M. Evaluating the concordance between BICLA and SRI4 in patients with systemic lupus erythematosus from the placebo arms of the EXPLORER and ATHOS trials. *Lupus Sci Med*. 2025 May 19;12(1):e001483.
6. Connelly K, Koelmeyer R, Ayton D, May J, Gregory K, Eades LE, Barallon R, Kandane-Rathnayake R, Golder V, Anzum A, Mydin M, Akther M, Friedman A, Askanase AD, Aranow C, **Vital E**, Pons-Estel G, Brunner H, Kalunian K, Dantata K, Arnaud L, Burke L, Simon LS, Zuraw Q, Garces S, Werth VP, Sun YB, Tanaka Y, Lahoud Y, Cornet A, Sorrentino A, Rahman A, Stevens A, Barbey C, Dey ID, Karis E, Bonfá E, Noss E, Smith EMD, Stojan G, Andersen J, Merola JF, Ross Terres JA, Buie J, Maller J, Mosca M, Hojnik M, Dall'Era M, Furie RA, van Vollenhoven RF, Banerjee S, Morand E; TRM-SLE Taskforce Members; Delphi Participants. Domains for inclusion in a novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): results of a modified Delphi study. *Lupus Sci Med*. 2025 May 6;12(1):e001484.
7. Mahmoud K, Md Yusof MY, Teh LS, Khan S, Yee CS, D'Cruz D, Isenberg D, Ciurtin C, Conaghan PG, Emery P, Edwards CJ, Hensor EMA, **Vital EM**. Improving the arthritis component of the SLEDAI-2K Rheumatology (Oxford). 2025 Jun 1;64(6):3556-3562.
8. Arnold J, Carter LM, Md Yusof MY, Dutton K, Wigston Z, Dass S, Wood S, Relton S, **Vital EM**. ANA-associated arthritis: clinical and biomarker characterization of a population for basket trials. *Rheumatology (Oxford)*. 2024 Nov 1;63(11):3135-3145.
9. Mucke J, Bertsias G, Aringer M, Arnaud L, Boström C, Cervera R, Chehab G, Cziráj L, Dreyer LW, Inês L, Jacobsen S, Nielsen CK, Marasco E, Mosca M, Myllys K, Pamfil C, Pego-Reigosa JM, Richter JG, Sciascia S, Tamirou F, Tsang-A-Sjoe M, **Vital EM**, Van Vollenhoven R, Wincup C, Schneider M. EULAR recommendations for a core dataset to support clinical care and translational and observational research in systemic lupus erythematosus. *Ann Rheum Dis*. 2025 Aug 20:S0003-4967(25)04234-7
10. Tansley SL, McMorow F, Cotton CV, Adamali H, Barratt SL, Betteridge ZE, Perurena-Prieto J, Gibbons MA, Kular R, Loganathan A, Lamb JA, Lu H, New RP, Pratt D, Rivera-Ortega P, Sayers R, Steward M, Stranks L, **Vital E**, Spencer LG, McHugh NJ, Cooper RG; UK-BILD Collaboration. Identification of

connective tissue disease autoantibodies and a novel autoantibody anti-annexin A11 in patients with "idiopathic" interstitial lung disease. *Clin Immunol.* 2024 May;262:110201.

11. Abacar K, De Marco G, Weddell J, Meridor K, Macleod T, Scarsbrook A, Mankia K, **Vital E**, Barr A, Pease C, Marzo-Ortega H, Mackie SL, McGonagle D. Late-Onset Spondylarthritis Presenting as Glucocorticoid-Resistant Polymyalgia Rheumatica: A hitherto underappreciated entity where TNF or IL-17 Blockade may have a Therapeutic Role. *Arthritis Rheumatol.* 2025 Jul 22. doi: 10.1002/art.43320.
12. Wiley MM, Radziszewski M, Khatri B, Joachims ML, Tessneer KL, Stolarczyk AM, Yao S, Li J, Pritchett-Frazee C, Johnston AA, Rasmussen A, Anaya JM, Aqrabi LA, Bae SC, Baecklund E, Björk A, Brun JG, Bucher SM, Dand N, Eloranta ML, Engelke F, Forsblad-d'Elia H, Fugmann C, Glenn SB, Gong C, Gottenberg JE, Hammenfors D, Imgenberg-Kreuz J, Jensen JL, Johnsen SJA, Jonsson MV, Kelly JA, Khanam S, Kim K, Kvarnström M, Mandl T, Martín J, Morris DL, Nocturne G, Norheim KB, Olsson P, Palm Ø, Pers JO, Rhodus NL, Sjöwall C, Skarstein K, Taylor KE, Tombleson P, Thorlacius GE, Venuturupalli SR, **Vital EM**, Wallace DJ, Radfar L, Brennan MT, James JA, Scofield RH, Gaffney PM, Criswell LA, Jonsson R, Appel S, Eriksson P, Bowman SJ, Omdal R, Rönnblom L, Warner BM, Rischmueller M, Witte T, Farris AD, Mariette X, Shiboski CH; Sjögren's International Collaborative Clinical Alliance (SICCA); Wahren-Herlenius M, Alarcón-Riquelme ME; PRECISEADS Clinical Consortium; Ng WF; UK Primary Sjögren's Syndrome Registry; Sivils KL, Guthridge JM, Adrianto I, Vyse TJ, Tsao BP, Nordmark G, Lessard CJ. Variants in the DDX6-CXCR5 autoimmune disease risk locus influence the regulatory network in immune cells and salivary gland. *Ann Rheum Dis.* 2025 May 29:S0003-4967(25)00949-5.
13. Arnaud L, Ruiz-Irastorza G, Aranow C, Bernatsky S, Dall'Era M, Adelowo O, Bae SC, Beretta L, Bonfa E, Cervera R, Chasset F, Clarke AE, Costedoat-Chalumeau N, Doria A, Espinosa G, Fanouriakis A, Fredi M, Gatto M, Gladman DD, Gomez-Puerta JA, Inanç M, Ines LS, Isenberg D, Izuka S, Khmelinskii N, Legge A, Macieira C, Monticelo OA, Morand EF, Muñoz-Louis R, Padjen I, Petri M, Piga M, Pons-Estel BA, Ramirez GA, Ramsey-Goldman R, Richez C, Sciascia S, Toro-Gutierrez CE, Van Vollenhoven RF, **Vital EM**, Gerosa M, Touma Z, Mosca M, Tani C; European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal, Diseases; Systemic Lupus Erythematosus International Collaborating Clinics group; European Lupus Society rare systemic lupus erythematosus taskforce member panel. ERN ReCONNECT-SLICC-SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestations. *Lancet Rheumatol.* 2025 Jul;7(7):e505-e518. doi: 10.1016/S2665-9913(25)00063-3.
14. Askanase AD, **Vital EM**, Meier O, Turchetta A, Mao HA, Maller J, Ross Terres JA, Dall'Era M. Evaluating the concordance between BICLA and SRI4 in patients with systemic lupus erythematosus from the placebo arms of the EXPLORER and ATHOS trials. *Lupus Sci Med.* 2025 May 19;12(1):e001483.
15. Connelly K, Koelmeyer R, Ayton D, May J, Gregory K, Eades LE, Barallon R, Kandane-Rathnayake R, Golder V, Anzum A, Mydin M, Akther M, Friedman A, Askanase AD, Aranow C, **Vital E**, Pons-Estel G, Brunner H, Kalunian K, Dantata K, Arnaud L, Burke L, Simon LS, Zuraw Q, Garces S, Werth VP, Sun YB, Tanaka Y, Lahoud Y, Cornet A, Sorrentino A, Rahman A, Stevens A, Barbey C, Dey ID, Karis E, Bonfá E, Noss E, Smith EMD, Stojan G, Andersen J, Merola JF, Ross Terres JA, Buie J, Maller J, Mosca M, Hojnik M, Dall'Era M, Furie RA, van Vollenhoven RF, Banerjee S, Morand E; TRM-SLE Taskforce Members; Delphi Participants. Domains for inclusion in a novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): results of a modified Delphi study *Lupus Sci Med.* 2025 May 6;12(1):e001484.
16. Carter L, Md Yusof MY, Wigston Z, Plant D, Wenlock S, Alase A, Psarras A, **Vital EM**. Blood RNA-sequencing across the continuum of ANA-positive autoimmunity reveals insights into initiating immunopathology *Ann Rheum Dis.* 2024.
17. Baker R, Sharfian H, Newcombe PJ, Gavin PG, Lazarus MN, Ramaswamy M, White WI, Ferrari N, Muthus D, Tummala R, Morand E, Furie R, **Vital EM**, Chamberlain C, Platt A, Al-Mossawi, H, Brohawn PZ, Csomor

- E. Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials *Ann Rheum Dis.* 2024.
18. Mahmoud K, Md Yusof MY, Teh LS, Khan S, Yee CD, D'Cruz D, Isenberg D, Ciurtin C, Conaghan PG, Emery P, Edwards C, Hensor EMA, **Vital EM**. Improving the arthritis component of the SLEDAI-2K. *Rheumatology (Oxford)* 2024 Dec 19
  19. Arnold J, Carter LM, Md Yusof MY, Dutton K, Wigston Z, Dass S, Wood S, Relton S, **Vital EM**. ANA-associated arthritis: clinical and biomarker characterization of a population for basket trials. *Rheumatology (Oxford)*. 2024 Nov 1;63(11):3135-3145
  20. Tansley SL, McMorrow F, Cotton CV, Adamali H, Barratt SL, Betteridge ZE, Perurena-Prieto J, Gibbons MA, Kular R, Loganathan A, Lamb JA, Lu H, New RP, Pratt D, Rivera-Ortega P, Sayers R, Steward M, Stranks L, **Vital E**, Spencer LG, McHugh MJ, Cooper RG, UK-BILD Consortium. Identification of connective tissue disease autoantibodies and a novel autoantibody anti-annexin A11 in patients with "idiopathic" interstitial lung disease. *Clin Immunol.* 2024 May;262:110201
  21. Ibrahim ST, Edwards CJ, Ehrenstein MR, Griffiths B, Gordon C, Hewins P, Jayne D, Lightstone L, McLaren Z, Rhodes B, **Vital EM**, Reynolds JA. Differences in management approaches for lupus nephritis within the UK. *Rheumatol Adv Pract.* 2024 Feb 9;8(1):rkae017.
  22. Bertsias G, Askanase A, Doria A, Saxena A, **Vital EM**. A path to Glucocorticoid Stewardship: a critical review of clinical recommendations for the treatment of systemic lupus erythematosus. *Rheumatology (Oxford)*. 2024 Jul 1;63(7):1837-1849.
  23. Md Yusof MY, Smith EMD, Ainsworth S, Armon K, Beresford MW, Brown M, Cherry L, Edwards CJ, Flora K, Gilman R, Griffiths B, Gordon C, Howard P, Isenberg D, Jordan N, Kaul A, Lanyon P, Laws PM, Lightstone L, Lythgoe H, Mallen CD, Marks SD, Maxwell N, Moraitis E, Nash C, Pepper RJ, Pilkington C, Psarras A, Rostron H, Skeates J, Skeoch S, Tremarias D, Wincup C, Zoma A, **Vital EM**. Management and treatment of children, young people and adults with systemic lupus erythematosus: British Society for Rheumatology guideline scope. *Rheumatol Adv Pract.* 2023 Dec 5;7(3):rkad093.
  24. Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, Boletis J, Bruce IN, Cervera R, Doria A, Dörner T, Furie RA, Gladman DD, Houssiau FA, Inês LS, Jayne D, Kouloumas M, Kovács L, Mok CC, Morand EF, Moroni G, Mosca M, Mucke J, Mukhtyar CB, Nagy G, Navarra S, Parodis I, Pego-Reigosa JM, Petri M, Pons-Estel BA, Schneider M, Smolen JS, Svenungsson E, Tanaka Y, Tektonidou MG, Teng YO, Tincani A, **Vital EM**, van Vollenhoven RF, Wincup C, Bertsias G, Boumpas. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. *Ann Rheum Dis.* 2024 Jan 2;83(1):15-29. doi: 10.1136/ard-2023-224762.
  25. Connelly K, Eades LE, Koelmeyer R, Ayton D, Golder V, Kandane-Rathnayake R, Gregory K, Brunner H, Burke L, Arnaud L, Askanase A, Aranow C, **Vital E**, Pons-Estel G, Dantata K, Andersen J, Cornet A, Buie J, Sun Y, Tanaka Y, Simon L, Lahoud Y, Friedman A, Kalunian K, Zuraw Q, Werth V, Garces S, Morand EF; TRM-SLE Consortium. Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce. *Nat Rev Rheumatol.* 2023 Sep;19(9):592-602.
  26. Akthar M, Nair N, Carter LM, **Vital EM**, Sutton E, McHugh N; British Isles Lupus Assessment Group Biologics Register (BILAG BR) Consortium; MASTERPLANS Consortium; Bruce IN, Reynolds JA. Deconvolution of whole blood transcriptomics identifies changes in immune cell composition in patients with systemic lupus erythematosus (SLE) treated with mycophenolate mofetil. *Arthritis Res Ther.* 2023 Jun 30;25(1):111.

27. Sandler RD, **Vital EM**, Mahmoud K, Prabu A, Riddell C, Teh LS, Edwards CJ, Yee CS. Revision to the musculoskeletal domain of the BILAG-2004 index to incorporate ultrasound findings. *Rheumatology* (Oxford). 2024 Feb 1;63(2):498-505.
28. Carter LM, Wigston Z, Laws P, **Vital EM**. Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers. *Br J Dermatol*. 2023 Jul 17;189(2):210-218.
29. Rodríguez-Carrio J, Burska A, Conaghan PG, Dik WA, Biesen R, Eloranta ML, Cavalli G, Visser M, Boumpas DT, Bertsias G, Wahren-Herlenius M, Rehwinkel J, Frémond ML, Crow MK, Ronnblom L, **Vital E**, Versnel M. Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider. *RMD Open*. 2023 Mar;9(1):e002864.
30. Burska A, Rodríguez-Carrio J, Biesen R, Dik WA, Eloranta ML, Cavalli G, Visser M, Boumpas DT, Bertsias G, Wahren-Herlenius M, Rehwinkel J, Frémond ML, Crow MK, Ronnblom L, Conaghan PG, Versnel M, **Vital E**. Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider. *RMD Open*. 2023 Mar;9(1):e002876.
31. Javier Rodríguez-Carrio<sup>1\*</sup>, Agata N. Burska<sup>2\*</sup>, Philip G Conaghan<sup>1</sup>, Willem A. Dik<sup>3</sup>, Robert Biesen<sup>4</sup>, Maija-Leena Eloranta<sup>5</sup>, Giulio Cavalli<sup>6</sup>, Marianne Visser<sup>7</sup>, Dimitrios Boumpas<sup>8</sup>, George Bertsias<sup>9</sup>, Marie Wahren-Herlenius<sup>10,11</sup>, Jan Rehwinkel<sup>12</sup>, Marie-Louise Frémond<sup>13</sup>, Mary K. Crow<sup>14</sup>, Lars Ronnblom<sup>5</sup>, Marjan A. Versnel<sup>15†</sup>, **Edward M. Vital<sup>2†</sup>** 2022 EULAR Points to Consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice. *Ann Rheum Dis* 2023 (in press)
32. Morand EF, **Vital EM**, Petri M, van Vollenhoven R, Wallace DJ, Mosca M, Furie RA, Silk ME, Dickson CL, Meszaros G, Jia B, Crowe B, de la Torre I, Dörner T. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). *Lancet*. 2023 Mar 25;401(10381):1001-1010.
33. Md Yusof MY, Arnold J, Saleem B, Vandeveld C, Dass S, Savic S, Vital EM, Emery P. Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study. *Lancet Rheumatol*. 2023 Feb;5(2):e88-e98. doi: 10.1016/S2665-9913(23)00004-8. Epub 2023 Jan 10.
34. Carter LM, Alase A, Wigston Z, Psarras A, Burska A, Sutton E, Md Yusof MY, Reynolds JA; Masterplans Consortium; McHugh N, Emery P, Wittmann M, Bruce IN, **Vital EM**. Gene expression and autoantibody analysis reveals distinct ancestry-specific profiles associated with response to rituximab in refractory systemic lupus erythematosus. *Arthritis Rheumatol*. 2022 Nov 21. doi: 10.1002/art.42404. Online ahead of print.
35. Robinson JI, Md Yusof MY, Davies V, Wild D, Morgan M, Taylor JC, El-Sherbiny Y, Morris DL, Liu L, Rawstron AC, Buch MH, Plant D, Cordell HJ, Isaacs JD, Bruce IN, Emery P, Barton A, Vyse TJ, Barrett JH, Morgan AW, **Vital EM**; MATURE Consortium; MASTERPLANS Consortia. Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity. *EBioMedicine*. 2022 Dec;86:104343. doi: 10.1016/j.ebiom.2022.104343. Epub 2022 Nov 11.
36. Psarras A, **Vital EM**. Anti-BDCA2 Antibody for Cutaneous Lupus Erythematosus. *N Engl J Med*. 2022 Oct 20;387(16):1528-1529. doi: 10.1056/NEJMc2211121.

37. Khan S, **Vital EM**, Patil A, Currie S, Backhouse O, Alty J. Systemic lupus erythematosus-induced intracranial hypertension: rare but important. *Pract Neurol*. 2022 Jul 18;pn-2022-003424. doi: 10.1136/practneurol-2022-003424. Online ahead of print.
38. Pepple S, Arnold J, **Vital EM**, Rawstron AC, Pease CT, Dass S, Emery P, Md Yusof MY. Predicting Sustained Clinical Response to Rituximab in Moderate to Severe Systemic Manifestations of Primary Sjögren Syndrome. *ACR Open Rheumatol*. 2022 Aug;4(8):689-699. doi: 10.1002/acr2.11466. Epub 2022 Jun 5.
39. Antonios Psarras, Adewonuola Alase, Agne Antanaviciute, Ian M. Carr, Md Yuzaiful Md Yusof, MiriamWittmann, Paul Emery, George C. Tsokos, **Edward M. Vital**. Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity. *Nature Communications* 11, 6149 (2020).
40. **Vital EM**, Merrill JT, Morand EF, Furie RA, Bruce IN, Tanaka Y, Manzi S, Kalunian KC, Kalyani RN, Streicher K, Abreu G, Tummala R. Anifrolumab Efficacy and Safety by Type I Interferon Gene Signature and Clinical Subgroups in Patients With SLE: Post Hoc Analysis of Pooled Data From 2 Phase 3 Trials. *Ann Rheum Dis*. 2022 Mar 25;annrheumdis-2021-221425. doi: 10.1136/annrheumdis-2021-221425.
41. Arnold J, Dass S, Twigg S, Jones CH, Rhodes B, Hewins P, Chakravorty M, Courtney P, Ehrenstein M, Md Yusof MY, **Vital EM**. Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab. *Rheumatology (Oxford)*. 2022 Mar 10;keac150. doi: 10.1093/rheumatology/keac150.
42. Arnold J, **Vital EM**, Dass S, Aslam A, Rawstron AC, Savic S, Emery P, Md Yusof MY. A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis. *Front Immunol*. 2022 Jan 12;12:803175. doi: 10.3389/fimmu.2021.803175.
43. Carter LM, Gordon C, Yee CS, Bruce I, Isenberg D, Skeoch S, **Vital EM**. Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index. *Rheumatology (Oxford)*. 2022 Jan 25;keab883. doi: 10.1093/rheumatology/keab883. Online ahead of print.
44. Md Yusof MY, **Vital EM**. Early intervention in systemic lupus erythematosus: time for action to improve outcomes and health-care utilization *Rheumatol Adv Pract*. 2021 Dec 28;6(1):rkab106. doi: 10.1093/rap/rkab106. eCollection 2022.
45. Muhammad Shipa, Andrew Embleton-Thirsk, Mariea Parvaz, Liliana Ribeiro Santos, Patrick Muller, Kashfia Chowdhury, David A Isenberg, Caroline J Doré, Caroline Gordon, Michael R Ehrenstein, BEAT-LUPUS Investigators; David P D'Cruz, Natasha Jordan, Benjamin Parker, Liz Lightstone, Alan Salama, Deborah Pyne, Christopher J Edwards, Bridget Griffiths, **Edward M Vital**, Benjamin Rhodes, Chee-Seng Yee, Mohammed Akil, Peter Topham, Nicola J Gullick. Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus : A Randomized Controlled Trial. *Ann Intern Med*. 2021 Dec;174(12):1647-1657. doi: 10.7326/M21-2078. Epub 2021 Oct 26.
46. Furie R, Morand EF, Askanase AD, **Vital EM**, Merrill JT, Kalyani RN, et al. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. *Lupus*. 2021 Jul; 30(8):1254-1263.
47. Watad A, De Marco G, Mahajna H, Druyan A, Eltity M, Hijazi N, Haddad A, Elias M, Zisman D, Naffaa ME, Brodavka M, Cohen Y, Abu-Much A, Abu Elhija M, Bridgewood C, Langevitz P, McLorinan J, Bragazzi NL, Marzo-Ortega H, Lidar M, Calabrese C, Calabrese L, **Vital E**, Shoenfeld Y, Amital H, McGonagle D. Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination. *Vaccines (Basel)*. 2021 Apr 29; 9(5).

48. Batten I, Robinson MW, White A, Walsh C, Fazekas B, Wyse J, Buettner A, D'Arcy S, Greenan E, Murphy CC, Wigston Z, Gabhann-Dromgoole JN, **Vital EM**, Little MA, Bourke NM. Investigation of type I interferon responses in ANCA-associated vasculitis. *Sci Rep*. 2021 Apr 15; 11(1):8272.
49. Mahmoud K, Zayat AS, Yusof MYM, Dutton K, Teh LS, Yee CS, D'Cruz D, Ng N, Isenberg D, Ciurtin C, Conaghan PG, Emery P, Edwards CJ, Hensor EMA, **Vital EM**. Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For mUsculoskeletal Lupus longitudinal multicentre study. *Rheumatology (Oxford)*. 2021 Nov 3; 60(11):5194-5204.
50. Ponchel F, Churchman S, El-Jawhari JJ, Burska AN, Chambers P, **Vital EM**, et al. Interleukin-7: a potential factor supporting B-cell maturation in the rheumatoid arthritis synovium. *Clin Exp Rheumatol*. 2021 Mar-Apr; 39(2):253-262.
51. Aringer M, Brinks R, Dörner T, Daikh D, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Schmajuk G, Tani C, Tedeschi SK, Touma Z, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Cziráj L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, **Vital EM**, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Costenbader K, Johnson SR. European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. *Ann Rheum Dis*. 2021 Feb 10;annrheumdis-2020-219373. doi: 10.1136/annrheumdis-2020-219373.
52. Johnson SR, Brinks R, Costenbader KH, Daikh D, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Cziráj L, Doria A, Graninger WB, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, **Vital EM**, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Aringer M. Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. *Ann Rheum Dis*. 2020 Oct;79(10):1333-1339. doi: 10.1136/annrheumdis-2020-217162. Epub 2020 Aug 14.
53. Aringer M, Brinks R, Dörner T, Daikh D, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Schmajuk G, Tani C, Tedeschi SK, Touma Z, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Cziráj L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, **Vital EM**, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Costenbader K, Johnson SR. European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. *Ann Rheum Dis*. 2021 Feb 10.
54. Psarras A, Antanaviciute A, Alase A, Carr I, Wittmann M, Emery P, Tsokos GC, **Vital EM**. TNF-alpha Regulates Human Plasmacytoid Dendritic Cells by Suppressing IFN-alpha Production and Enhancing T Cell Activation. *J Immunol*. 2021 Feb 15; 206(4):785-796.
55. Parodis I, **Vital EM**, Hassan SU, Jonsen A, Bengtsson AA, Eriksson P, et al. De novo lupus nephritis during treatment with belimumab. *Rheumatology (Oxford)*. 2021 Sep 1; 60(9):4348-4354.

56. Sabih Ul-Hassan, Md Yuzaiful Md Yusof, Paul Emery, Shouvik Dass, **Edward M Vital**. Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab. *Front. Med.*, 27 August 2020 | <https://doi.org/10.3389/fmed.2020.00498>
57. Yasser M. El-Sherbiny, Md Yuzaiful Md Yusof, Antonios Psarras, Elizabeth M.A. Hensor, Kumba Z. Kabba, Katherine Dutton, AlaaA.A. Mohamed, Dirk Elewaut, Dennis McGonagle, Reuben Tooze, Gina D oody, Miriam Wittmann, Paul Emery, **Edward Vital**. B cell tetherin: a flow-cytometric cell-specific assay for response to Type-I interferon predicts clinical features and flares in SLE. doi: 10.1002/art.41187.[Epub ahead of print] *Arthritis and Rheumatology*
58. Yusof MM, Britton J, Edward S, Hensor EMA, Goodfield MJ, Laws PM, Emery P, Wittmann M, **Vital EM**. Validity and sensitivity to change of laser Doppler imaging as a novel objective outcome measure for cutaneous lupus erythematosus. *Lupus*. 2019 Sep 14;961203319873977. doi: 10.1177/0961203319873977. [Epub ahead of print]
59. Shalbf M, Alase AA, Berekmeri A, Md Yusof MY, Pistolic J, Goodfield MJ, Edward S, Botchkareva NV, Stacey M, **Vital EM**, Wittmann M. Plucked hair follicles from patients with chronic discoid lupus erythematosus show a disease-specific molecular signature. *Lupus Sci Med*. 2019 Jul 14;6(1):e000328. doi: 10.1136/lupus-2019-000328. eCollection 2019.
60. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, **Vital EM**, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. *Ann Rheum Dis*. 2019 Sep;78(9):1151-1159. doi: 10.1136/annrheumdis-2018-214819. Epub 2019 Aug 5.
61. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, **Vital EM**, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. *Arthritis Rheumatol*. 2019 Sep;71(9):1400-1412. doi: 10.1002/art.40930. Epub 2019 Aug 6.
62. Stevens MJ, Walker-Bone K, Culliford DJ, Alcacer-Pitarch B, Blake A, Hopkinson N, Teh LS, **Vital EM**, Edwards CJ, Williams AE, Cherry L. Work participation, mobility and foot symptoms in people with systemic lupus erythematosus: findings of a UK national survey. *J Foot Ankle Res*. 2019 Apr 29;12:26. doi: 10.1186/s13047-019-0335-0. eCollection 2019.
63. Md Yusof MY, **Vital EM**, McElvenny DM, Hensor EMA, Das S, Dass S, Rawstron AC, Buch MH, Emery P, Savic S. Predicting severe infection and effects of hypogammaglobulinaemia during therapy with rituximab in rheumatic and musculoskeletal diseases. *Arthritis Rheumatol*. 2019 May 27. doi: 10.1002/art.40937. [Epub ahead of print]

64. Hassan SU, Mahmoud K, **Vital EM**. Assessment of responsiveness of the musculoskeletal component of SLE-DAS in an independent cohort. *Ann Rheum Dis*. 2019 Apr 25. [Epub ahead of print]
65. Mahmoud K, Zayat AS, Md Yusof MY, Hensor EM, Conaghan PG, Emery P, **Vital EM**. Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus. *Rheumatology* 2018 *Rheumatology* (Oxford). 2019 Jan 3;58(8):1353-60.
66. Zayat AS, Mahmoud K, Md Yusof MY, Mukherjee S, D'Agostino MA, Hensor EMA, Wakefield RJ, Conaghan PG, Edwards CJ, Emery P, **Vital EM**. Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus. *Rheumatology* (Oxford). 2018 Sep 27.
67. Md Yusof MY, Psarras A, El-Sherbiny YM, Hensor EMA, Dutton K, Ul-Hassan S, Zayat AS, Shalbaf M, Alase A, Wittmann M, Emery P, **Vital EM**. Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status. *Ann Rheum Dis*. 2018 Oct;77(10):1432-1439.
68. El-Sherbiny YM, Psarras A, Md Yusof MY, Hensor EMA, Tooze R, Doody G, Mohamed AAA, McGonagle D, Wittmann M, Emery P, **Vital EM**. A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features. *Sci Rep*. 2018 Apr 11;8(1):5793.
69. McCarthy EM, Sutton E, Nesbit S, White J, Parker B, Jayne D, Griffiths B, Isenberg DA, Rahman A, Gordon C, D'Cruz DP, Rhodes B, Lanyon P, **Vital EM**, Yee CS, Edwards CJ, Teh LS, Akil M, McHugh NJ, Zoma A, Bruce IN; British Isles Lupus Assessment Group Biologics Register. Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. *Rheumatology* (Oxford). 2018 Mar 1;57(3):470-479.
70. Daniel A, Bagnato G, **Vital E**, Del Galdo F. Chylous ascites in a patient with an overlap syndrome: a surprising response to rituximab. *BMJ Case Rep*. 2017 Oct 20;2017.
71. Md Yusof MY, Shaw D, El-Sherbiny YM, Dunn E, Rawstron AC, Emery P, **Vital EM**. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. *Ann Rheum Dis*. 2017 Nov;76(11):1829-1836.
72. McCarthy EM, Sutton E, Nesbit S, Parker B, Jayne D, Griffiths B, Isenberg DA, Rahman A, Gordon C, D'Cruz DP, Rhodes B, Lanyon P, **Vital EM**, Yee CS, Edwards CJ, Teh LS, Akil M, McHugh NJ, Zoma A, Bruce IN; British Isles Lupus Assessment Group Biologics Register. The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. *Rheumatology* (Oxford). 2017 Jun 1;56(6):1049.
73. Glinatsi D, Bird P, Gandjbakhch F, Haavardsholm EA, Peterfy CG, **Vital EM**, Emery P, Conaghan PG, Østergaard M. Development and Validation of the OMERACT Rheumatoid Arthritis Magnetic Resonance Tenosynovitis Scoring System in a Multireader Exercise. *J Rheumatol*. 2017 Nov;44(11):1688-1693.
74. Md Yusof MY, Kabia A, Darby M, Lettieri G, Beirne P, **Vital EM**, Dass S, Emery P. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre. *Rheumatology* (Oxford). 2017 Aug 1;56(8):1348-1357.
75. McCarthy EM, Sutton E, Nesbit S, Parker B, Jayne D, Griffiths B, Isenberg DA, Rahman A, Gordon C, D'Cruz DP, Rhodes B, Lanyon P, **Vital EM**, Yee CS, Edwards CJ, Teh LS, Akil M, McHugh NJ, Zoma A, Bruce IN; British Isles Lupus Assessment Group Biologics Register. The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. *Rheumatology* (Oxford). 2017 Jun 1;56(6):1041-1043.
76. Williams AE, Blake A, Cherry L, Alcacer-Pitarch B, Edwards CJ, Hopkinson N, **Vital EMJ**, Teh LS. Patients' experiences of lupus-related foot problems: a qualitative investigation. *Lupus*. 2017 Oct;26(11):1174-1181.

77. Cherry L, Alcacer-Pitarch B, Hopkinson N, Teh LS, **Vital EM**, Edwards CJ, Blake A, Williams AE. The prevalence of self-reported lower limb and foot health problems experienced by participants with systemic lupus erythematosus: Results of a UK national survey. *Lupus*. 2017 Apr;26(4):410-416
78. Care MA, Stephenson SJ, Barnes NA, Fan I, Zougman A, El-Sherbiny YM, **Vital EM**, Westhead DR, Tooze RM, Doody GM. Network Analysis Identifies Proinflammatory Plasma Cell Polarization for Secretion of ISG15 in Human Autoimmunity. *J Immunol*. 2016 Aug 15;197(4):1447-59.
79. Williams AE, Cherry L, Blake A, Alcacer-Pitarch B, Edwards C, Hopkinson N, **Vital E**, The LS. An Investigation into the Scale and Impact of Self-Reported Foot Problems Associated with Systemic Lupus Erythematosus: A Study Protocol and Survey Questionnaire Development. *Musculoskeletal Care*. 2016 Jun;14(2):110-5.
80. Sellam J, Rivière E, Courties A, Rouzaire PO, Toluoso B, **Vital EM**, Emery P, Ferracioli G, Soubrier M, Ly B, Hendel Chavez H, Taoufik Y, Dougados M, Mariette X. Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. *Arthritis Res Ther*. 2016 Dec 13;18(1):294.
81. Cherry L, Alcacer-Pitarch B, Hopkinson N, Teh LS, **Vital EM**, Edwards CJ, Blake A, Williams AE. The prevalence of self-reported lower limb and foot health problems experienced by participants with systemic lupus erythematosus: Results of a UK national survey. *Lupus*. 2016 Sep 29.[Epub ahead of print]
82. Care MA, Stephenson SJ, Barnes NA, Fan I, Zougman A, El-Sherbiny YM, **Vital EM**, Westhead DR, Tooze RM, Doody GM. Network Analysis Identifies Proinflammatory Plasma Cell Polarization for Secretion of ISG15 in Human Autoimmunity. *J Immunol*. 2016 Aug 15;197(4):1447-59.
83. Zayat AS, Md Yusof MY, Wakefield RJ, Conaghan PG, Emery P, **Vital EM**. The role of ultrasound in assessing musculoskeletal symptoms of systemic lupus erythematosus: a systematic literature review. *Rheumatology (Oxford)*. 2016 Mar;55(3):485-94.
84. Alase AA, El-Sherbiny YM, **Vital EM**, Tobin DJ, Turner NA, Wittmann M. IFN $\lambda$  Stimulates MxA Production in Human Dermal Fibroblasts via a MAPK-Dependent STAT1-Independent Mechanism. *J Invest Dermatol*. 2015 Aug 19.
85. Md Yusof MY, **Vital EM**, Das S, Dass S, Arumugakani G, Savic S, Rawstron AC, Emery P. Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions. *Ann Rheum Dis*. 2015 Sep;74(9):1734-8.
86. **Vital EM**, Wittmann M, Edward S, Yusof Y, MacIver H, Pease CT, Goodfield M, Emery P. Responses to rituximab suggest B cell-independent inflammation in systemic lupus erythematosus. *Arthritis Rheumatol*. 2015 Jun;67(6):1586-91
87. **Vital EM**, Dass S, Buch MH, Rawstron AC, Emery P. An Extra Dose of Rituximab Improves Clinical Response in Rheumatoid Arthritis Patients with Initial Incomplete B cell Depletion: a Randomised Controlled Trial. *Ann Rheum Dis*. 2015 Jun;74(6):1195-201.
88. **Vital EM** and Das S, Horton S, Bryer D, El-Sherbiny Y, Rawstron AC, Ponchel F, Emery P, Buch MH. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? - non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. *Ann Rheum Dis*. 2014 May;73(5):909-12.
89. Ponchel F, **Vital EM**, Emery P. An immunological biomarker to predict methotrexate response in early RA. *Annals of the Rheumatic Diseases* 2013.

90. Das S, Fernandez Matilla M, Dass S, Buch MH, Rawstron AC, **Vital EM**, Emery P. Statins do not influence clinical response and B cell depletion after rituximab treatment in rheumatoid arthritis. *Ann Rheum Dis*. 2013 Mar;72(3):463-4.
91. Fabris M, Quartuccio L, **Vital EM**, Pontarini E, Salvin S, Fabro C, Zabotti A, Benucci M, Manfredi M, Ravagnani V, Biasi D, Atzeni F, Sarzi-Puttini P, Morassi P, Fischetti F, Bazzicchi L, Saracco M, Pellerito R, Cimmino M, Carraro V, Semeraro A, Schiavon F, Caporali R, Bortolotti R, Govoni M, Fogolari F, Tonutti E, Bombardieri S, Emery P, De Vita S. The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers. *Arthritis Rheum*. 2013 Jan;65(1):88-97.
92. **Vital EM**, Dass S, Emery P. Concomitant cyclophosphamide and oral immunosuppressants with rituximab for systemic lupus erythematosus. *Rheumatology (Oxford)*. 2012 Jun;51(6):1131-2.
93. Díaz-Lagares C, Croca S, Sangle S, **Vital EM**, Catapano F, Martínez-Berriotxo A, García-Hernández F, Callejas-Rubio JL, Rascón J, D'Cruz D, Jayne D, Ruiz-Irastorza G, Emery P, Isenberg D, Ramos-Casals M, Khamashta MA; UK-BIOGEAS Registry. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. *Autoimmun Rev*. 2012 Mar;11(5):357-64
94. **Vital EM**, Dass S, Buch MH, Henshaw, K, Pease CT, Martin MF, Ponchel F, Rawstron AC, Emery P. Rituximab responses in systemic lupus Erythematosus explained by B cell biomarkers. *Arthritis Rheum*. 2011 May 25. doi: 10.1002/art.30466. [Epub ahead of print]
95. **Vital EM**, Rawstron AC, Dass S, Henshaw K, Madden J, Emery P, McGonagle D. Reduced dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. *Arthritis Rheum*. 2011 Mar;63(3):603-8.
96. **Vital EM**, Dass S, Rawstron AC, Buch MH, Goeb V, Henshaw K, Ponchel F, Emery P. Management of non-response to rituximab: predictors and outcome of retreatment. *Arthritis Rheum*. 2010 May;62(5):1273-9.
97. **Vital EM**, Dass S, Buch MH, Rawstron AC, Ponchel F, McGonagle D, Emery P. Re-treatment of rheumatoid arthritis patients who were initial nonresponders to rituximab: comment on the article by Thurlings et al. *Arthritis Rheum*. 2009 Jun;60(6):1867
98. Dass S, **Vital EM**, Rawstron AC, McGonagle D, Emery P. Highly sensitive B cell analysis predicts response to rituximab in rheumatoid arthritis. *Arthritis Rheum*. 2008 Oct;58(10):2993-9.
99. Dass S, Bowman S, **Vital EM**, Ikeda K, Pease CT, Hamburger J, Richards A, Rauz S, Emery P. Reduction of fatigue in Sjogren's Syndrome with Rituximab: results of a randomised, double-blind, placebo-controlled pilot study. *Ann Rheum Dis*. 2008 Nov;67(11):1541-4
100. Dass S, **Vital EM** & Emery P. Development of psoriasis after B cell depletion with rituximab. *Arthritis rheum* 56, 2715-18 (2007).
101. Freeston JE, Conaghan PG, Dass S, **Vital E**, Hensor EM, Stewart SP, Emery P. Does extremity-MRI improve erosion detection in severely damaged joints? *Ann Rheum Dis*, 66, 1538-40 (2007).
102. **Vital EM**, Hutton CW, Hughes PM. Premature osteoarthritis of the knee associated with cartilage hypertrophy and phalangeal dysgenesis. *Skeletal Radiol*. 2005 Aug;34(8):494-7.

## Review Articles

1. Carter L, Ehrenstein MR, **Vital EM**. Evolution and trajectory of B cell targeted therapies in rheumatic diseases. *Lancet Rheumatology*. 2025
2. Stockfelt M, Teng O, **Vital EM**. Opportunities and limitations of B cell depletion approaches in SLE. *Nature Reviews Rheumatology*, 1-16, 2025.
3. Bertsias G, Askanase A, Doria A, Saxena A, **Vital EM**. A path to glucocorticoid stewardship: a critical review of clinical recommendations for the treatment of systemic lupus erythematosus. *Rheumatology (Oxford)* 2024.
4. Mathian A, Felten R, Alarcon Riquelme ME, Psarras A, Mertz P, Chasset F, **Vital EM**, Arnaud L. Les Interferons de type I: une cible therapeutique dans les maladies inflammatoires a mediation immunitaire (IMIDs)
5. Ines LS, Fedi M, Jesus D, Shumilova A, Franceschini F, **Vital EM**. What is the best instrument to measure disease activity in SLE? SLE-DAS vs. Easy-BILAG. *Autoimmunity Reviews* 2024. Jan;23(1): 103428.
6. Shumilova A, **Vital EM**. Musculoskeletal manifestations of systemic lupus erythematosus. *Best Practice Clinical Research Rheumatology* 2023 Dec;37(4): 101859.
7. Psarras A, Wittmann M, **Vital EM**. Emerging concepts of type I interferons in SLE pathogenesis and therapy. *Nat Rev Rheumatol*. 2022 Oct;18(10):575-590. doi: 10.1038/s41584-022-00826-z. Epub 2022 Sep 12.
8. Aringer M, Alarcon Riquelme ME, Clowse M, Pons-Estel GJ, **Vital EM**, Dall-Era M. A glimpse into the future of systemic lupus erythematosus. *The Adv Musculoskelet Dis* 2022 Mar 30:14
9. **Vital EM**, Dorner T, Ohrndorf S, Alten R, Bello N, Haladyk E, Burmester G. A narrative literature review comparing the key features of musculoskeletal involvement in rheumatoid arthritis and systemic lupus erythematosus. *Rheumatol. Ther.* 2022 Jun;9(3):781-802.
10. Carter LM, McGonagle D, **Vital EM**, Wittmann M. Applying Early Intervention Strategies to Autoimmune Skin Diseases. Is the Window of Opportunity Preclinical? A Dermato-Rheumatology Perspective *J Invest Dermatol*. 2022 Jan 13:S0022-202X(21)02532-X. doi: 10.1016/j.jid.2021.11.018. Online ahead of print.
11. Garcia-Montoya L, Villota-Eraso C, Md Yusof MY, **Vital EM**, Emery P. Lessons for rituximab therapy in patients with rheumatoid arthritis. *Lancet Rheumatology* 2020 Aug;2(8):e497-e509.
12. Berekméri A, Tiganescu A, Alase AA, **Vital EM**, Stacey M, Wittmann M. Non-invasive Approaches for the Diagnosis of Autoimmune/Autoinflammatory Skin Diseases-A Focus on Psoriasis and Lupus erythematosus. *Front Immunol*. 2019 Aug 21;10:1931. doi: 10.3389/fimmu.2019.01931. eCollection 2019.
13. Psarras A, Emery P, **Vital EM**. Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. *Rheumatology (Oxford)*. 2017 Oct 1;56(10):1662-1675.
14. Mahmoud K, Zayat A, **Vital EM**. Musculoskeletal manifestations of systemic lupus erythematosus. *Curr Opin Rheumatol*. 2017 Sep;29(5):486-492.
15. Pentony P, Duquenne L, Dutton K, Mankia K, Gul H, **Vital E**, Emery P. The initiation of autoimmunity at epithelial surfaces: a focus on rheumatoid arthritis and systemic lupus erythematosus. *Discov Med*. 2017 Nov;24(133):191-200.

16. Romão VC, **Vital EM**, Fonseca JE, Buch MH. Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis? *Arthritis Res Ther*. 2017 Oct 24;19(1):239.
17. Mahmoud K, Zayat A, **Vital EM**. Musculoskeletal Manifestations of SLE. Under Review, *Current Opinion in Rheumatology*.
18. Md Yusof MY, **Vital EM**, Buch MH. B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use. *Curr Rheumatol Rep*. 2015 Oct;17(10):65.
19. Ponchel F, Burska AN, **Vital EM**. Pharmacogenomics in rheumatoid arthritis: how close are we to the clinic? *Pharmacogenomics*. 2014 Jul;15(10):1275-9.
20. Yusof MY, **Vital EM**, Emery P. Biologics in systemic lupus erythematosus: current options and future perspectives. *Br J Hosp Med (Lond)*. 2014 Aug;75(8):440-7.
21. Burska AN, Hunt L, Boissinot M, Strollo R, Ryan BJ, **Vital E**, Nissim A, Winyard PG, Emery P, Ponchel F. Autoantibodies to posttranslational modifications in rheumatoid arthritis. *Mediators Inflamm*. 2014;2014:492873.
22. Md Yusof My, **Vital EM**, Emery P. B cell targeted therapies in systemic lupus erythematosus and ACNA-associated vasculitis: current progress. *Expert Review Clin Immunol*. 2013
23. **Vital EM**, Kay J, Emery P. Rituximab biosimilars. *Expert Opin Biol Ther*. 2013 Apr 22.
24. Ponchel F, **Vital EM**, Kingsbury SR, El-Sherbiny YM. CD4+ T cell subsets in rheumatoid arthritis. *Int J Clinical Rheumatology*. 2012 Feb;7(1):37-53
25. **Goëb V**, Buch MH, Vital EM, Emery P. Costimulation blockade in rheumatic diseases: where are we? *Curr Opin Rheumatol*. 2009 May;21(3):244-50.
26. **Vital EM**, Emery P. The development of targeted therapies in rheumatoid arthritis. *J Autoimmun*. 2008 Nov;31(3):219-27.
27. **Vital EM**, Emery P. Abatacept in the treatment of rheumatoid arthritis. *Ther Clin Risk Manag*. Vol 2(4):365-75 (2008)
28. Dass S., **Vital EM** & Emery P. Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis. *Expert opin pharmacotherapy* 7, 2559-2570 (2006).
29. Dass S, **Vital.E.**, Emery P. Rituximab: B-cell depletion therapy for the treatment of rheumatoid arthritis. *Future Rheumatol* 1, 293-302 (2006).
30. **Vital, E.M.** & Emery, P. Abatacept. *Drugs Today (Barc)* 42, 87-93 (2006)
31. Mackie SL, **Vital EM**, Ponchel F & Emery P. Co-stimulatory blockade as therapy for rheumatoid arthritis. *Current rheumatology reports* 7, 400-6 (2005).

## Editorials

1. Psarras A. and **Vital EM**. Keratinocytes: from passive targets to active mediators of systemic autoimmunity. *Sci Transl Med*. 2022 Apr 27;14(642)
2. Bosello SL, **Vital EM**, Del Galdo F. More to B: the growing evidence to inform targeting B cells in scleroderma. *Rheumatology (Oxford)*. 2022 Dec 5;keac677. doi: 10.1093/rheumatology/keac677. Online ahead of print.
3. Dumitru R, Buch M, **Vital EM**. The Law of the Vital Few: choosing parameters of disease activity in rheumatoid arthritis. *J Rheum (in press)*
4. Aringer M & **Vital EM**. Lots of autoantibodies equals lupus? *Arthri Res Ther*. 2013.
5. **Vital, E.M.** & Emery, P. Advances in the treatment of early rheumatoid arthritis. *Am family physician* 72, 1002, 1004 (2005).

## Chapters in edited books

1. Psarras A and Vital EM. Systemic Lupus Erythematosus. In *Oxford Textbook of Rheumatology (2023)*

2. Alcacer-Pitarch B, **Vital EM**, Buch MH. Autoimmune Connective Tissue Diseases. In *The foot and ankle in rheumatology*, Oxford 2019
3. Yusof Md, **Vital EM**, Emery P. Rituximab. In *Rheumatology*, Mosby 2019
4. Yusof Md, **Vital EM**, Emery P. Rituximab. In *Rheumatology*, Mosby 2016
5. Freeston JE, **Vital EM**. Ultrasound in Rheumatology. In *Medicine*
6. **Vital EM**. Rituximab. In *Atlas of Rheumatology*, 2013
7. **Vital EM**, Dass S, Emery P. B cell depletion. In *Rheumatology*, Mosby 2013.
8. Dass S, **Vital EM**, Emery P. B cell depletion. In *Rheumatology*, Mosby 2010.
9. **Vital E.M.**, Dass S., Emery P. B Cell Targets in Rheumatoid Arthritis. In *New Therapeutic Targets in Rheumatoid Arthritis*. Birkhauser. (2009)
10. Dass S, **Vital EM**, Emery P. Rituximab. In *Rheumatoid Arthritis*, Mosby 2008.
11. **Vital EM**, Emery P. Rheumatic manifestations of malignant haematological conditions. *Reports on the rheumatic diseases* Feb 2007. Arthritis Research Campaign.

**Chapel Allerton Hospital  
Chapeltown Road  
Leeds LS7 4SA  
United Kingdom**

Prof Luis Iñes  
President, SLEuro Executive Committee

31 January 2026

Dear Professor Iñes and Executive Committee members,

Thank you for considering my re-application as the general secretary of SLEuro, a role that I have enjoyed over the past four years. In that time I have been able to support the president and executive committee in the growth of the society into new areas including all but one of the Advanced Workshops since inception, further development of the training bursary scheme into the new mentorship scheme, proposing new executive committee members, proposing potential funded research projects, oversight of European meetings and budgets and help networking with industry. For example, recently I was able to propose a late-breaking deadline for the European Lupus Meeting then ensure that a positive phase 3 trial would premier at our meeting attracting press interest. As a host for the training bursary scheme I have hosted very successful visitors who each published numerous papers and continued our academic relationship after their visits to Leeds.

It would give me great satisfaction to provide continuity to the next president and committee.

In this role I will be able to bring to SLEuro:

- Extensive networking with industry to continue to attract funding and collaboration.
- Extensive networking with other international lupus organisations such as TRM-SLE and TransformLupus including leading an industry funded proposal to combine multiple national registries
- Industry-funded research proposal enrolling SLEuro members and contributory sites, now in advanced negotiations with the funder
- Ongoing speaking at Advanced workshops and SLEuro mentorship
- I will bring my experience as the chair of BILAG to suggest initiatives for Europe. In this role we have ongoing activities under the headings: (i) Developing and promoting the BILAG index; (ii) steering the BILAG Biologics Registry; (iii) developing the next generation of lupus experts; (iv) conducting collaborative research studies; (v) education and policies to improve the care of lupus patients. All of these activities could be extended to a European level
- I will use my knowledge of both clinical and translational research methods to ensure that the society's activities represent the interests of all stakeholders involved in SLE care and research

Yours sincerely,



**Edward M Vital FRCP PhD**  
Professor of Translational Medicine  
Leeds Institute of Rheumatic and Musculoskeletal Medicine | University of Leeds